10x Genomics, Inc. ($TXG) Stock Forecast: Up 5.0% Today

What is 10x Genomics, Inc.?

10X Genomics (NASDAQ: TXG) is a biotechnology company acclaimed for its innovative contributions to the genomics sector. The company is making notable advancements in research and diagnostics with its state-of-the-art technologies.

Why is 10x Genomics, Inc. going up?

TXG stock is up 5.0% on Apr 30, 2026 15:26

• The rise in TXG stock today may be linked to Vanguard's notable ownership in the company, as both Vanguard Capital Management and Vanguard Portfolio Management have disclosed substantial holdings. This vote of confidence from a major investment firm likely influenced investor sentiment positively.
• The announcement of an upcoming virtual shareholder meeting by 10X Genomics, highlighting strong financial performance and a commitment to linking executive compensation to company achievements, could also be a factor driving the bullish trend. Investors may interpret the company's transparent governance and robust financials as signals of potential future growth.
• The combination of Vanguard's increased ownership and the promising insights shared in the shareholder meeting may have bolstered investor confidence, leading to the upward movement in TXG stock.

TXG Price Chart

TXG Technical Analysis

TXG News

Vanguard holds 6.17M shares of 10X Genomics (NASDAQ: TXG), 5.24% stake

Vanguard Capital Management has reported a 5.24% stake in 10X Genomics (NASDAQ: TXG), holding 6,166,597 shares of common stock. This Schedule 13G filing indicates Vanguard has sole dispositive power over all these shares but sole voting power over 897,011 shares. The disclosure clarifies that these holdings are managed by Vanguard Capital Management LLC and its specified affiliates.

https://www.stocktitan.net/sec-filings/TXG/schedule-13g-10x-genomics-inc-passive-investment-disclosure-5-7c91984a66ce.html

Vanguard Portfolio Management reports 6.98M TXG shares (NASDAQ: TXG)

Vanguard Portfolio Management has reported a beneficial ownership of 6,981,683 shares of 10X Genomics Inc. (NASDAQ: TXG) common stock, which represents 5.93% of the class. This disclosure, filed as a Schedule 13G, indicates that Vanguard holds sole dispositive power over these shares for various funds and client accounts. The filing explicitly states that the acquisition is for investment purposes in the ordinary course of business and is not intended to change or influence the control of the issuer.

https://www.stocktitan.net/sec-filings/TXG/schedule-13g-10x-genomics-inc-passive-investment-disclosure-5-4ef6aaebc44e.html

10x Genomics (TXG) details 2026 virtual meeting, director votes and Say on Pay

10x Genomics is holding its 2026 annual shareholder meeting virtually on June 4, 2026, to address the election of three Class I directors, the ratification of Ernst & Young LLP as auditor, and an advisory "Say on Pay" vote on executive compensation. The company reported $643 million in revenue for 2025, a 69% gross margin, and $523 million in cash, cash equivalents, and marketable securities, reflecting a resilient performance despite macroeconomic challenges. Executive compensation is structured to align with performance through a mix of salary, annual incentives tied to financial and strategic objectives, and performance-based equity awards linked to total shareholder return and revenue growth.

https://www.stocktitan.net/sec-filings/TXG/def-14a-10x-genomics-inc-definitive-proxy-statement-9a0e86c5ca17.html

Trending Today

Arista Networks Inc. ($ANET) Stock Forecast: Down 15.7% Today

Lam Research Corporation ($LRCX) Stock Forecast: Up 7.5% Today

Tandem Diabetes Care, Inc. ($TNDM) Stock Forecast: Down 6.0% Today

Super Micro Computer Inc ($SMCI) Stock Forecast: Up 23.2% Today

Upstart Holdings Inc. ($UPST) Stock Forecast: Down 9.5% Today

Internationa Flavors & Fragrances Inc. ($IFF) Stock Forecast: Up 17.2% Today

Circle Internet Group ($CRCL) Stock Forecast: Up 6.0% Today

Devon Energy Corporation ($DVN) Stock Forecast: Down 8.6% Today

Taiwan Semiconductor Manufacturing Company Ltd. ($TSM) Stock Forecast: Up 6.3% Today

Lemonda Inc. ($LMND) Stock Forecast: Down 5.1% Today

10x Genomics, Inc. Price History

08.03.2026 - TXG Stock was up 5.2%

• Positive sentiment towards the biotechnology sector likely influenced the bullish movement in TXG stock today.
• The lack of analyst ratings and earnings data may have heightened speculation and volatility in the stock's price.
• Promotional activities such as a virtual trading conference and free trade alerts might have enticed more investors to engage with the stock, fueling its upward trajectory.
• The rise in TXG stock price could be attributed to a mix of sector optimism, speculative trading, and increased investor interest due to promotional efforts.

27.03.2026 - TXG Stock was up 5.2%

• The anticipation surrounding the upcoming virtual shareholder meeting and the disclosed information on director votes and executive compensation likely bolstered investor confidence, showcasing the company's commitment to transparency and strong governance.
• Positive financial outcomes for 2025, highlighted by increased revenue and gross margin, might have fueled investor optimism concerning the company's future growth prospects.
• The company's strategic approach to linking executive compensation with performance indicators such as total shareholder return and revenue growth underscores its dedication to enhancing shareholder value. This alignment potentially heightened investor confidence and contributed to the positive market momentum.

31.02.2026 - TXG Stock was up 9.0%

• The stock of 10x Genomics (TXG) saw a significant bullish movement recently.
• This upward trend in the stock price followed the CEO's sale of 15,000 shares of Class A Common Stock for a total of $288,908. The sale was part of a pre-arranged trading plan. Simultaneously, the company was involved in new projects like the STELA project and had received higher price targets from analysts.
• While concerns surrounding institutional selling and new AI models were present, the positive company developments and the CEO's stock sale likely fueled the stock's upward trajectory.
• Vanguard's restructuring in reporting its TXG shares, though not directly impacting the stock price, contributes to the overall narrative of investor activity involving the company.

21.03.2026 - TXG Stock was down 5.2%

• A recent sale of 5,000 shares by the CEO in a pre-arranged trade plan raised concerns among investors, possibly indicating a lack of confidence in the company's short-term performance.
• The CEO's share sale may have sparked worries about future growth and financial results, leading to a negative sentiment among investors and a decline in the stock price.
• Some investors viewed the CEO's actions as a potential insider signal, prompting them to sell their TXG positions and contributing to the stock price drop during the trading day.

06.02.2026 - TXG Stock was down 5.0%

• The bearish movement in TXG's stock price could be attributed to the CEO selling a significant number of shares, which might have raised concerns among investors about the company's future prospects.
• The filing of a Form 144 by an affiliate proposing to sell Class A Common stock could have also contributed to the downward pressure on the stock, signaling potential insider sentiment or profit-taking.
• Despite the recent strong earnings and raised price targets by analysts, the selling activity by key company figures and affiliates may have created uncertainty among investors, leading to the bearish market movement in TXG today.
• The influx of RSUs being granted to company directors and officers, while designed for retention and performance alignment, could also have added to the selling pressure on the stock as recipients may choose to liquidate some of their holdings.

20.02.2026 - TXG Stock was up 5.4%

• The bullish movement in TXG could be attributed to the positive sentiment surrounding the company's innovative technologies in biological analysis, which are in high demand by various institutions.
• Technical analyses and trade ideas may have also contributed to increased investor confidence in the stock, leading to a surge in buying activity.
• The focus on genomics and biotechnology companies like 10x Genomics in ETF holdings, as seen in the Ark Genomic Revolution UCITS ETF (AAKG), could have further bolstered interest and investment in TXG, driving its bullish movement.

30.03.2026 - TXG Stock was up 5.0%

• The rise in TXG stock today may be linked to Vanguard's notable ownership in the company, as both Vanguard Capital Management and Vanguard Portfolio Management have disclosed substantial holdings. This vote of confidence from a major investment firm likely influenced investor sentiment positively.
• The announcement of an upcoming virtual shareholder meeting by 10X Genomics, highlighting strong financial performance and a commitment to linking executive compensation to company achievements, could also be a factor driving the bullish trend. Investors may interpret the company's transparent governance and robust financials as signals of potential future growth.
• The combination of Vanguard's increased ownership and the promising insights shared in the shareholder meeting may have bolstered investor confidence, leading to the upward movement in TXG stock.

25.02.2026 - TXG Stock was up 8.8%

• An amendment to Schedule 13G by Vanguard for 10X Genomics indicates a potential shift in investment strategy or portfolio reallocation.
• The disclosure that Vanguard holds 0 shares in TXG may have eased concerns about market influence or regulatory issues, boosting investor confidence.
• This update likely contributed to the positive movement in TXG's stock, showcasing stability and transparency in the company's shareholder base and appealing to market participants.

14.03.2026 - TXG Stock was up 5.2%

• The positive performance of TXG stock today seems to be influenced by favorable market sentiment towards the biotech industry.
• Despite questions about profitability and valuation, the company's robust financial position and growth opportunities may have attracted investors.
• Investor enthusiasm for 10X Genomics Inc.'s innovation and future market possibilities might have also contributed to the uptrend in the stock.
• In sum, today's bullish movement in TXG stock reflects investors' optimism regarding the company's long-term potential, despite some lingering financial considerations.

29.03.2026 - TXG Stock was down 5.2%

• The bearish movement in TXG stock today could be attributed to Vanguard Portfolio Management's disclosure of holding over 6.9 million shares of the company, which may have raised concerns among investors about potential selling pressure.
• Additionally, the upcoming virtual shareholder meeting where executive compensation, director votes, and other key decisions will be discussed might have created uncertainty in the market, leading to a negative sentiment towards the stock.
• Despite the company's strong financial performance in 2025, including impressive revenue and cash reserves, the focus on executive compensation and corporate governance issues may have overshadowed these positive aspects, contributing to the bearish trend in TXG stock.

27.02.2026 - TXG Stock was down 5.3%

• The decline in TXG stock today may be linked to the CEO's substantial selling of shares, sparking investor worries about the company's future.
• Despite recent stock gains, positive projects like STELA, and raised price targets from analysts, concerns over internal issues or confidence in growth plans may have been hinted at by the CEO's share selling.
• Institutional selling and apprehensions about a new AI model could also have played a part in the negative outlook on TXG stock, diverting attention from positive developments and analyst support.

19.02.2026 - TXG Stock was up 5.1%

• The bullish movement in TXG stock today could be attributed to positive sentiment in the biotechnology sector, driven by advancements in genomic technologies and their increasing importance in various industries.
• Listing the holdings of the Ark Genomic Revolution UCITS ETF (AAKG) may have highlighted the strong presence of genomics companies like Twist Bioscience Corp. and CRISPR Therapeutics AG, which could have boosted investor confidence in companies like TXG that operate in a similar space.
• Investors may view TXG as a promising player in the genomics industry, especially with the growing focus on healthcare innovation and personalized medicine, leading to increased buying interest and driving the stock price higher.